Medical geneticists evaluating prenatal abnormalities have demonstrated how integrating multiple cytogenetic and molecular technologies can resolve complex chromosomal arrangements and guide clinical management in cases of mosaic isodicentric Y chromosomes. Isodicentric Y chromosomes represent structural chromosome abnormalities that arise primarily through sister chromatid fusion or aberrant chromosomal recombination following structural breaks on the Y chromosome. Because chromosomes with two centromeres are inherently unstable during mitotic cell division, they frequently generate dynamic mosaic patterns involving multiple distinct lineages, with a monosomy 45,X cell line occurring most frequently. In clinical practice, disorders of sex development linked to such aberrations are rarely identified during the prenatal period compared to postnatal presentations, creating significant diagnostic and prognostic challenges for clinicians and prospective parents alike.
To investigate the genotype-phenotype correlations and diagnostic pathways associated with this condition, investigators conducted comprehensive diagnostic evaluations on three fetuses undergoing invasive testing at a hospital molecular genetic center between January 2022 and December 2024. The diagnostic indications that initiated these evaluations differed across the cohort, reflecting the varied prenatal presentations of sex chromosome abnormalities. For the first two cases, invasive amniocentesis was prompted by noninvasive prenatal testing results that indicated sex chromosome deficiencies, whereas the third case was identified following routine prenatal ultrasonography that revealed structural fetal abnormalities, specifically an echogenic intracardiac focus accompanied by narrowing of the aorta. In all three instances, clinicians obtained amniotic fluid samples alongside peripheral blood from both biological parents to establish whether the observed chromosomal aberrations arose de novo or were inherited from parental carriers.
To obtain an unambiguous view of the underlying genetic structures, the clinical team deployed four complementary diagnostic modalities: G-banded karyotyping of cultured cells, chromosomal microarray analysis using gene chips, fluorescence in situ hybridization targeting chromosome-specific probes, and real-time quantitative polymerase chain reaction. Cultured amniotic fluid cells were harvested after eight to ten days of incubation, while parental peripheral lymphocytes were cultured for three days. Following colcemid arrest, hypotonic processing, fixation, and G-banding, metaphase chromosomes were scanned and enumerated in accordance with the International System for Human Cytogenomics Nomenclature. Parental karyotypes across all three cases were completely normal, confirming that the structural chromosomal rearrangements detected in each fetus had occurred as de novo mutational events.
High-resolution molecular testing provided essential clarity regarding the exact breakpoints and gene dosage alterations that conventional karyotyping alone could not fully disentangle. Chromosomal microarray analysis performed on extracted amniotic fluid DNA mapped copy number variations across the genome, while fluorescence in situ hybridization verified cell lineages directly in uncultured cells to avoid culture-induced selection artifacts. For the first fetus, G-banding showed a mosaic karyotype containing three distinct cell lines: a predominant 45,X lineage, a secondary cell line carrying an isodicentric Y chromosome with a short-arm breakpoint, and a minor normal 46,XY lineage. Interphase fluorescence in situ hybridization using probes against SRY and the X-chromosome centromere corroborated the presence of all three cell populations, albeit with minor proportion discrepancies attributed to sampling variation and differences between cultured and uncultured cell states.
Detailed mapping in the first fetus showed a 2.1-megabase deletion within the pseudoautosomal region originating from the Yp11.32 locus, together with a mosaic 26.1-megabase deletion spanning the Yp11.31q11.23 segment. The loss of the pseudoautosomal segment resulted in haploinsufficiency of the short stature homeobox gene, a critical regulator of skeletal chondrogenesis that contributes to short stature in affected individuals. Quantitative polymerase chain reaction further verified that despite the proximity of the breakpoint to the sex-determining region, the SRY gene remained intact alongside an intact azoospermia factor region. Following multidisciplinary genetic counseling, the expectant parents acknowledged the documented developmental and growth risks but elected to continue the gestation to term.
Evaluation of the second and third fetuses revealed distinct structural rearrangements situated along the long arm of the Y chromosome, demonstrating the molecular heterogeneity of isodicentric Y aberrations. In the second fetus, G-banded cytogenetics identified a triple-mosaic karyotype consisting of a major 45,X line alongside cells harboring an isodicentric Y with a long-arm breakpoint and a minor cell line possessing a deleted Y chromosome. Chromosomal microarray analysis mapped precise deletions including a 6.5-megabase mosaic loss at Yp11.31p11.2, a 2.9-megabase loss at Yq11.221, and a complete 9.2-megabase deletion encompassing Yq11.221q11.23. Quantitative testing established that this extensive rearrangement resulted in the complete absence of the AZFb and AZFc regions, which govern spermatogenesis and whose absence is clinically associated with complete azoospermia in adulthood.
In the third fetus, cytogenetic and microarray investigations identified a dual-mosaic pattern dominated by a 45,X cell line accompanied by an isodicentric Y chromosome defined by a breakpoint at Yq11.223. Microarray analysis uncovered a mosaic duplication measuring 16.9 megabases on Yp11.31q11.223 and a complete 4.7-megabase deletion across Yq11.223q11.23. Unlike the second case, sequence-tagged site amplification confirmed that the microdeletion in the third fetus was restricted specifically to the AZFc locus while sparing the AZFb region. Although individuals with isolated AZFc deletions exhibit variable fertility profiles that may allow successful intracytoplasmic sperm injection, deletions spanning both AZFb and AZFc result in absolute spermatogenic failure, leaving donor insemination as the sole reproductive option.
The clinical course of the live-born infant from the first pregnancy underscored the unpredictable phenotypic spectrum and management complexities associated with mosaic sex chromosome conditions. During routine third-trimester ultrasound monitoring at 37 weeks of gestation, clinicians detected an unexpected right adrenal mass in the developing fetus. The infant was delivered alive displaying externally normal male genitalia. At one month of age, pediatric surgeons successfully performed a surgical resection of the adrenal mass, which was histopathologically confirmed to be an adrenal neuroblastoma. Longitudinal follow-up assessments through 23 months of age revealed normal physical appearance, age-appropriate growth and developmental milestones, and no signs of oncologic recurrence, highlighting the value of diligent postnatal surveillance.
To place these clinical observations within a broader context, the authors synthesized their findings with 47 previously documented prenatal cases from the cytogenetic literature, analyzing a combined cohort of 50 fetuses with isodicentric Y chromosomes. Within this 50-case series, 39 fetuses were male, three were female, three presented with ambiguous gonads, and six had undetermined sexual differentiation. Pregnancy outcomes comprised 32 live births, 15 elected pregnancy terminations, and three cases with undocumented outcomes. Among the live-born infants, eight exhibited clinical abnormalities, which most commonly consisted of ambiguous genitalia, short stature, or structural cardiac anomalies. Rare co-occurring conditions, including complex cardiac malformations, multiple structural defects, and the adrenal neuroblastoma identified in the current study, could not be directly attributed to the isodicentric Y karyotype alone and likely reflect complex developmental or environmental factors.
These collective observations emphasize that the proportion of 45,X mosaicism measured in prenatal amniotic fluid does not reliably predict postnatal anatomical phenotypes. Because amniotic fluid cell lineages do not directly reflect the mosaic proportions within developing gonadal tissues, high circulating levels of 45,X cells do not inevitably prevent masculine external development. Nevertheless, affected individuals face ongoing developmental liabilities, including risks of short stature from SHOX deletions, adolescent gonadal dysgenesis, and adult infertility stemming from azoospermia factor losses. Consequently, the authors conclude that combining multitechnology cytogenetic platforms with comprehensive prenatal counseling and individualized, long-term pediatric follow-up provides the most effective pathway for managing mosaic isodicentric Y chromosome conditions.
Subject of Research: Prenatal diagnosis and pregnancy outcomes of mosaic isodicentric Y chromosome abnormalities
Article Title: Prenatal diagnosis, genetic analysis, and pregnancy outcomes of fetuses with mosaic isodicentric Y chromosomes
Article References: Gao, T., Wei, H., Zheng, Y., Xiao, Y., Zheng, M., & Hong, S. (2026). Prenatal diagnosis, genetic analysis, and pregnancy outcomes of fetuses with mosaic isodicentric Y chromosomes. Molecular Cytogenetics, 19(1), Article 16. https://doi.org/10.1186/s13039-026-00766-3
Image Credits: AI Generated
DOI: 10.1186/s13039-026-00766-3
Keywords: mosaic isodicentric Y chromosome, prenatal diagnosis, disorders of sex development, chromosomal microarray analysis, fluorescence in situ hybridization, karyotyping, real-time quantitative PCR, SRY gene, SHOX gene haploinsufficiency, azoospermia factor microdeletions, 45,X mosaicism, neuroblastoma, noninvasive prenatal testing, amniocutaneous fluid analysis, cytogenetics, genotype-phenotype correlation, structural chromosome aberrations, prenatal ultrasound anomalies
News Source: Drew Townsend. (November 19, 2026). Multitechnology Prenatal Testing Clarifies Outcomes for Fetuses With Mosaic Isodicentric Y Chromosomes. Scienmag.



